Introduction
============

Urine is an ideal biomarker resource. Blood often remains stable because of homeostatic mechanisms. However, as the filtrate of blood, urine has no need to remain stable and thus tolerates a much higher degree of changes. Therefore, urine can accumulate all changes from the whole body and may provide the potential to detect early and small changes in the body ([@ref-7]). Urine is easily affected by various physiological factors, such as sex, age and diet ([@ref-26]). In patients, the urine proteome is easily influenced by certain medications because of necessary therapeutic measures. Therefore, our laboratory proposed a strategy for urinary biomarker studies. First, we used animal models to find early biomarkers of related diseases. Then, we verified candidate biomarkers in clinical urine samples ([@ref-8]). The use of animal models minimizes external influencing factors, such as diet, gender, age, medications and some environmental factors. In addition, using animal models will allow identification of the exact start of the disease, which is helpful in the early detection of cancer. Differential urinary proteins found in animal models are likely to be directly associated with related diseases. According to this strategy, our laboratory has applied different types of animal models, such as subcutaneous tumor-bearing model ([@ref-27]), pulmonary fibrosis model ([@ref-28]), glioma model ([@ref-17]), liver fibrosis model ([@ref-30]), Alzheimer's disease model ([@ref-31]), chronic pancreatitis model ([@ref-33]) and myocarditis model ([@ref-35]), to search for early biomarkers before pathological changes and clinical manifestations.

Urine can reflect changes more sensitively than blood. It has been reported that even when interference is introduced into the blood with two anticoagulants, changes in the abundance of more proteins were consistently detected in urine samples than in plasma ([@ref-14]). In addition, the urine proteome has been applied to detect tumors in various tumor-bearing animals. For example, (i) in W256 subcutaneously tumor-bearing rats, a total of ten differential urinary proteins were identified before a tumor mass was palpable ([@ref-27]); (ii) in the intracerebral W256 tumor model, nine urinary proteins changed significantly before any obvious clinical manifestations or abnormal magnetic resonance imaging (MRI) signals ([@ref-34]); (iii) in the glioma rat model, a total of thirty differential proteins were identified before MRI ([@ref-17]); (iv) a total of seven urinary proteins changed in both lung tumor-bearing mice and lung cancer patients, indicating their potential roles in the early detection of lung cancer ([@ref-32]); (v) in a urothelial carcinoma rat model, differential urinary proteins from upregulated biological processes might be seen as candidate biomarkers ([@ref-6]). All of these studies were performed involving thousands of tumor cells; however, no tumor starts from a thousand tumor cells. Since urine is a more sensitive biomarker resource than blood, we explored the sensitivity limit of urine. We determined whether the urine proteome changes if there are only a small number of tumor cells in the body.

In this study, we subcutaneously injected approximately ten Walker-256 carcinosarcoma cells into nine rats. Urine samples were collected on days 0, 13, and 21. Urine proteins were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Differential proteins on days 13 and 21 were analyzed by functional enrichment analysis to find associations with tumor progression. This research aimed to determine whether the urine proteome could reflect changes associated with these ten tumor cells. The technical flowchart is presented in [Fig. 1](#fig-1){ref-type="fig"}.

![Workflow of protein identification in rats subcutaneously inoculated with ten tumor cells.\
Urine was collected on days 0, 13 and 21 after inoculation with tumor cells. Urinary proteins were extracted, digested, and identified by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Functional enrichment analysis of differential proteins was performed by DAVID and IPA.](peerj-07-7717-g001){#fig-1}

Material and Methods
====================

Animal treatment
----------------

Male Wistar rats (*n* = 12, 150 ± 20 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. Animals were maintained with a standard laboratory diet under controlled indoor temperature (21 ± 2 °C), humidity (65--70%) and 12 h/12 h light--dark cycle conditions. The experiment was approved by Peking Union Medical College (Approval ID: ACUC-A02-2014-008).

Walker-256 (W256) carcinosarcoma cells were purchased from the Cell Culture Center of the Chinese Academy of Medical Sciences (Beijing, China). W256 tumor cells were intraperitoneally inoculated into Wistar rats. The W256 ascites tumor cells were harvested from the peritoneal cavity after seven days. After two cell passages, the W256 ascites tumor cells were collected, centrifuged, and resuspended in 0.9% normal saline (NS). Then, W256 tumor cells were serially diluted to a concentration of 10^2^/mL. The viability of W256 cells was evaluated by the Trypan blue exclusion test using a Neubauer chamber, and only 95% viable tumor cells were used for serially dilution.

The rats were randomly divided into the following two groups: rats subcutaneously inoculated with tumor cells (*n* = 9) and control rats (*n* = 3). In the experimental group, rats were inoculated with 10 W256 cells in 100 µL of NS into the right flank of the rats. The control rats were subcutaneously inoculated with an equal volume of NS. All rats were anesthetized with sodium pentobarbital solution (four mg/kg) before inoculation.

Urine collection
----------------

Before urine collection, all rats were accommodated in metabolic cages for 2--3 days. Urine samples were collected from rats subcutaneously inoculated with tumor cells (*n* = 9) on days 0, 13 and 21. All rats were placed in metabolic cages individually for 12 h to collect urine without any treatment. After collection, urine samples were stored immediately at −80 °C.

Extraction and digestion of urinary proteins
--------------------------------------------

Urine samples (*n* = 27) were centrifuged at 12,000 × g for 30 min at 4 °C. Then, the supernatants were precipitated with three times the volume of ethanol at −20 °C overnight. The pellets were dissolved sufficiently in lysis buffer (8 mol/L urea, 2 mol/L thiourea, 50 mmol/L Tris, and 25 mmol/L DTT). After centrifugation at 4 °C and 12,000 × g for 30 min, the protein samples were measured by using the Bradford assay. A total of 100 µg of each protein sample was digested with trypsin (Trypsin Gold, Mass Spec Grade, Promega, Fitchburg, WI, USA) by using filter-aided sample preparation (FASP) methods ([@ref-25]). These digested peptides were desalted using Oasis HLB cartridges (Waters, Milford, MA, USA) and then dried by vacuum evaporation (Thermo Fisher Scientific, Bremen, Germany).

LC-MS/MS analysis
-----------------

Digested peptides (*n* = 27) were dissolved in 0.1% formic acid to a concentration of 0.5 µg/µL. For analysis, one µg of peptide from each sample was loaded into a trap column (75 µm ×2 cm, three µm, C18, 100 Å) at a flow rate of 0.25 µL/min and then separated with a reversed-phase analytical column (75 µm ×250 mm, two µm, C18, 100 Å). Peptides were eluted with a gradient extending from 4%--35% buffer B (0.1% formic acid in 80% acetonitrile) for 90 min and then analyzed with an Orbitrap Fusion Lumos Tribrid Mass Spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). The MS data were acquired using the following parameters: (i) data-dependent MS/MS scans per full scan were auquired at the top-speed mode; (ii) MS scans had a resolution of 120,000, and MS/MS scans had a resolution of 30,000 in Orbitrap; (iii) HCD collision energy was set to 30%; (iv) dynamic exclusion was set to 30 s; (v) the charge-state screening was set to +2 to +7; and (vi) the maximum injection time was 45 ms. Each peptide sample was analyzed twice.

Label-free quantification
-------------------------

Raw data files (*n* = 54) were searched using Mascot software (version 2.5.1; Matrix Science, London, UK) against the Swiss-Prot rat database (released in February 2017, containing 7,992 sequences). The parent ion tolerance was set to 10 ppm, and the fragment ion mass tolerance was set to 0.02 Da. The carbamidomethylation of cysteine was set as a fixed modification, and the oxidation of methionine was considered a variable modification. Two missed trypsin cleavage sites were allowed, and the specificity of trypsin digestion was set for cleavage after lysine or arginine. Dat files (*n* = 54) were exported from Mascot software and then processed using Scaffold software (version 4.7.5, Proteome Software Inc., Portland, OR). The parameters were set as follows: both peptide and protein identifications were accepted at a false discovery rate (FDR) of less than 1.0% and proteins were identified with at least two unique peptides. Different samples were compared after normalization with the total spectra. Protein abundances at different time points were compared with spectral counting, according to previously described procedures ([@ref-18]; [@ref-23]).

Statistical analysis
--------------------

Average normalized spectral counts of each sample were used for the following statistical analysis. The levels of proteins identified on days 13 and 21 were compared with their levels on day 0. Differential proteins were selected with the following criteria: unique peptides ≥2; fold change ≥1.5 or ≤0.67; average spectral count in the high-abundance group ≥3; comparison between two groups were conducted using two-sided, unpaired *t*-test; and *P*-values of group differences were adjusted by the Benjamini and Hochberg method ([@ref-2]). Group differences resulting in adjusted *P*-values \<0.05 were considered statistically significant. All results are expressed as the mean ± standard deviation.

Functional enrichment analysis
------------------------------

Differential proteins on days 13 and 21 were analyzed by Gene Ontology (GO) based on the biological process, cellular component and molecular function categories using the Database for Annotation, Visualization and Integrated Discovery (DAVID) ([@ref-13]). The biological pathway enrichment at the two time points was analyzed with IPA software (Ingenuity Systems, Mountain View, CA, USA).

Results
=======

Characterization of rats subcutaneously inoculated with tumor cells
-------------------------------------------------------------------

A total of 12 male Wistar rats (150 ± 20 g) were randomly divided into the following two groups: a control group (*n* = 3) and a group of rats subcutaneously inoculated with W256 tumor cells (*n* = 9). The body weight of these 12 rats was recorded every 3--5 days, and the daily behavior changes of the two groups were observed. The body weight of the group of rats subcutaneously inoculated with W256 tumor cells was slightly lower than that of the rats in the control group, but there were no significant differences until day 41 ([Fig. 2](#fig-2){ref-type="fig"}). In addition, we did not observe any detectable tumor mass in the whole period. The rats in the control group performed normal daily activities and had shiny hair. There were no significant differences in daily behavior between these two groups.

![Body weight changes between the rats subcutaneously inoculated with tumor cells and the control rats.](peerj-07-7717-g002){#fig-2}

![Proteomic analysis of urine samples on days 13 and 21 in rats subcutaneously inoculated with tumor cells.\
(A) Unsupervised cluster analysis of all proteins identified by LC-MS/MS. (B) Overlap evaluation of the differential proteins identified on days 13 and 21.](peerj-07-7717-g003){#fig-3}

Urine proteome changes
----------------------

Twenty-seven urine samples at three time points (days 0, 13, and 21) were used for label-free LC-MS/MS quantitation. A total of 824 urinary proteins with at least 2 unique peptides were identified with \<1% FDR at the protein level ([Table S1](#supp-3){ref-type="supplementary-material"}). A hierarchical clustering was performed by using the complete linkage method. As shown in [Fig. 3A](#fig-3){ref-type="fig"}, all technical replications within one sample were clustered together, indicating that the technical variation was smaller than the interindividual variation. In addition, all 824 proteins were clustered into three clusters, which almost corresponded to the urine proteome samples from the same group on day 0, day 13 and day 21 (except rat4-D0 and rat6-D21), indicating that intragroup technical variation was smaller than the intergroup biological variation and showed good consistency among these nine rats when inoculated with the same limited number of tumor cells. Using screening criteria, 34 and 59 differential proteins were identified on days 13 and 21, respectively. The overlap of these differential proteins is shown by a Venn diagram in [Fig. 3B](#fig-3){ref-type="fig"}. Details are presented in [Table 1](#table-1){ref-type="table"}.

Functional analysis
-------------------

Functional enrichment analysis of differential proteins was performed by DAVID ([@ref-13]). Differential proteins were classified into biological processes, cellular components and molecular functions. The major biological pathways of differential proteins were enriched by IPA software. A significance threshold of *P* \< 0.05 was used in all these representative lists.

Lists of fourteen representative biological processes on days 13 and 21 are presented in [Fig. 4A](#fig-4){ref-type="fig"}. Cell adhesion, negative regulation of endopeptidase activity and organ regeneration were overrepresented both on days 13 and 21. Blood coagulation, acute-phase response, autophagic cell death, positive regulation of cell proliferation, extracellular matrix organization, and response to glucose were independently overrepresented on day 13. On day 21, heterophilic cell--cell adhesion via plasma membrane cell adhesion molecules, proteolysis, positive regulation of phagocytosis and angiogenesis were independently enriched.
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###### Differentially proteins identified on day 13 and day 21.

![](peerj-07-7717-g005)

  Uniprot ID   Human ortholog   Description                                                          Trends   ANOVA *P*-value   Average fold change   
  ------------ ---------------- -------------------------------------------------------------------- -------- ----------------- --------------------- ------
  P02761       NO               Cluster of Major urinary protein                                     ↑        \<0.00010         4.70                  7.59
  P06760       P08236           Beta-glucuronidase                                                   ↑        0.0073            3.56                  4.55
  Q9JI85       P80303           Nucleobindin-2                                                       ↑        0.00018           2.74                  3.69
  P27590       P07911           Uromodulin                                                           ↑        \<0.00010         2.31                  2.65
  P97603       Q92859           Neogenin (Fragment)                                                  ↓        \<0.00010         0.43                  0.21
  P20611       P11117           Lysosomal acid phosphatase                                           ↓        \<0.00010         0.56                  0.46
  Q9ESS6       P50895           Basal cell adhesion molecule                                         ↓        \<0.00010         0.56                  0.40
  Q63556       NO               Serine protease inhibitor A3M (Fragment)                             ↓        \<0.00010         0.47                  0.48
  O35112       Q13740           CD166 antigen                                                        ↓        \<0.00010         0.41                  0.33
  Q63416       Q06033           Inter-alpha-trypsin inhibitor heavy chain H3                         ↓        \<0.00010         0.32                  0.23
  O70535       P42702           Leukemia inhibitory factor receptor                                  ↓        \<0.00010         0.29                  0.35
  P13596       P13591           Neural cell adhesion molecule 1                                      ↓        \<0.00010         0.28                  0.36
  P35444       P49747           Cartilage oligomeric matrix protein                                  ↓        \<0.00010         0.27                  0.42
  P07897       P16112           Aggrecan core protein                                                ↓        \<0.00010         0.23                  0.30
  P26453       P35613           Basigin                                                              ↓        0.00094           0.23                  0.21
  Q9EPF2       P43121           Cell surface glycoprotein MUC18                                      ↓        \<0.00010         0.18                  0.08
  P38918       O95154           Aflatoxin B1 aldehyde reductase member 3                             ↑        0.0028            3.36                  --
  Q63530       Q96BW5           Phosphotriesterase-related protein                                   ↑        0.0004            3.18                  --
  P24268       P07339           Cathepsin D                                                          ↑        \<0.00010         1.56                  --
  P18292       P00734           Prothrombin                                                          ↓        \<0.00010         0.60                  --
  P04937       P02751           Fibronectin                                                          ↓        \<0.00010         0.61                  --
  P08592       NO               Amyloid beta A4 protein                                              ↓        \<0.00010         0.56                  --
  Q91XN4       Q13145           BMP and activin membrane-bound inhibitor homolog                     ↓        0.003             0.55                  --
  Q9JLS4       Q6FHJ7           Secreted frizzled-related protein 4                                  ↓        0.00053           0.52                  --
  Q63467       P04155           Trefoil factor 1                                                     ↓        0.00026           0.50                  --
  Q62930       P02748           Complement component C9                                              ↓        0.0055            0.49                  --
  P24090       P02765           Alpha-2-HS-glycoprotein                                              ↓        0.00026           0.47                  --
  P97546       Q9Y639           Neuroplastin                                                         ↓        \<0.00010         0.47                  --
  P26644       P02749           Beta-2-glycoprotein 1                                                ↓        0.00016           0.46                  --
  Q5HZW5       Q9NPF0           CD320 antigen                                                        ↓        \<0.00010         0.45                  --
  Q8JZQ0       P09603           Macrophage colony-stimulating factor 1                               ↓        0.00013           0.42                  --
  P07154       P07711           Cathepsin L1                                                         ↓        0.00021           0.40                  --
  D3ZTE0       P00748           Coagulation factor XII                                               ↓        \<0.00010         0.25                  --
  P07171       P05937           Cluster of Calbindin                                                 ↓        \<0.00010         0.05                  --
  Q63475       Q92932           Receptor-type tyrosine-protein phosphatase N2                        ↓        \<0.00010         --                    6.25
  P00714       P00709           Alpha-lactalbumin                                                    ↑        \<0.00010         --                    3.77
  Q05175       P80723           Brain acid soluble protein 1                                         ↑        \<0.00010         --                    3.69
  Q4V885       Q5KU26           Collectin-12                                                         ↑        0.0011            --                    2.28
  O55004       P34096           Ribonuclease 4                                                       ↑        0.00023           --                    2.13
  P81828       NO               Urinary protein 2                                                    ↑        \<0.00010         --                    1.96
  P62986       P62987           Ubiquitin-60S ribosomal protein L40                                  ↑        0.0011            --                    1.81
  P36374       NO               Prostatic glandular kallikrein-6                                     ↑        0.0034            --                    1.78
  P80202       P36896           Activin receptor type-1B                                             ↑        \<0.00010         --                    1.76
  P06866       P00739           Haptoglobin                                                          ↑        0.00036           --                    1.68
  P07151       P61769           Beta-2-microglobulin                                                 ↑        \<0.00010         --                    1.65
  P08937       NO               Odorant-binding protein                                              ↑        0.002             --                    1.51
  P05544       NO               Serine protease inhibitor A3L                                        ↓        0.00026           --                    0.64
  P29598       P00749           Urokinase-type plasminogen activator                                 ↓        \<0.00010         --                    0.62
  P05545       NO               Serine protease inhibitor A3K                                        ↓        \<0.00010         --                    0.61
  Q01460       Q01459           Di-N-acetylchitobiase                                                ↓        \<0.00010         --                    0.61
  Q642A7       Q8WW52           Protein FAM151A                                                      ↓        0.00045           --                    0.58
  P21704       P24855           Deoxyribonuclease-1                                                  ↓        \<0.00010         --                    0.56
  P63018       P11142           Cluster of Heat shock cognate 71 kDa protein                         ↓        0.00045           --                    0.56
  P61972       P61970           Nuclear transport factor 2                                           ↓        0.0024            --                    0.54
  Q68FQ2       Q9BX67           Junctional adhesion molecule C                                       ↓        0.0011            --                    0.53
  P31211       P08185           Corticosteroid-binding globulin                                      ↓        0.00011           --                    0.48
  Q9R0T4       P12830           Cadherin-1                                                           ↓        \<0.00010         --                    0.47
  Q562C9       Q9BV57           1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase                 ↓        0.0057            --                    0.43
  O88917       NO               Adhesion G protein-coupled receptor L1                               ↓        \<0.00010         --                    0.42
  Q9WUW3       P05156           Complement factor I                                                  ↓        \<0.00010         --                    0.42
  P01026       P01024           Complement C3                                                        ↓        0.0071            --                    0.42
  P85971       O95336           6-phosphogluconolactonase                                            ↓        0.0005            --                    0.39
  Q63751       NO               Vomeromodulin (Fragment)                                             ↓        0.012             --                    0.31
  Q9EQV6       O14773           Tripeptidyl-peptidase 1                                              ↓        0.0033            --                    0.30
  P53813       P07225           Vitamin K-dependent protein S                                        ↓        0.00096           --                    0.29
  Q00657       Q6UVK1           Chondroitin sulfate proteoglycan 4                                   ↓        \<0.00010         --                    0.28
  P04073       P20142           Gastricsin                                                           ↓        0.00044           --                    0.27
  O70244       O60494           Cubilin                                                              ↓        \<0.00010         --                    0.25
  Q1WIM1       Q8NFZ8           Cell adhesion molecule 4                                             ↓        \<0.00010         --                    0.24
  Q5I0D5       Q9H008           Phospholysine phosphohistidine inorganic pyrophosphate phosphatase   ↓        \<0.00010         --                    0.20
  Q63678       P25311           Zinc-alpha-2-glycoprotein                                            ↓        \<0.00010         --                    0.20
  Q99PW3       Q99519           Sialidase-1                                                          ↓        0.00025           --                    0.18
  Q641Z7       Q92484           Acid sphingomyelinase-like phosphodiesterase 3a                      ↓        \<0.00010         --                    0.18
  P04785       P07237           Protein disulfide-isomerase                                          ↓        \<0.00010         --                    0.17
  Q6AYE5       Q86UD1           Out at first protein homolog                                         ↓        \<0.00010         --                    0.16
  P47820       P12821           Angiotensin-converting enzyme                                        ↓        0.0016            --                    0.13
  Q80WD1       Q86UN3           Reticulon-4 receptor-like 2                                          ↓        0.017             --                    0.04

![Functional analysis of differential proteins on days 13 and 21.\
(A) Dynamic changes in biological processes on day 13. (B) Dynamic changes in biological processes on day 21. (C) Dynamic changes in pathways on day 13. (D) Dynamic changes in pathways on day 21.](peerj-07-7717-g004){#fig-4}

To identify the biological pathways involved with the differential urine proteins, IPA software was used for canonical pathway enrichment analysis. A total of 18 and 13 significant pathways were enriched on days 13 and 21, respectively ([Fig. 4B](#fig-4){ref-type="fig"}). Among these pathways, enriched intrinsic prothrombin activation pathway, coagulation system, acute phase response signaling, extrinsic prothrombin activation pathway and NAD phosphorylation and dephosphorylation were overrepresented on days 13 and 21. In addition, some representative pathways, such as autophagy, phagosome maturation and the role of tissue factor in cancer, were independently enriched on day 13, and the complement system was enriched only on day 21.

The enriched cellular components and molecular functions are presented in [Fig. S1](#supp-1){ref-type="supplementary-material"}. The majority of differential proteins were derived from the extracellular exosomes, extracellular space and extracellular matrix ([Fig. S1A](#supp-1){ref-type="supplementary-material"}). In the molecular function category, serine-type endopeptidase inhibitor activity and calcium ion binding were overrepresented on both on days 13 and 21 ([Fig. S1B](#supp-1){ref-type="supplementary-material"}).

Random allocation statistical analysis
--------------------------------------

To confirm that these differential proteins on days 13 and 21 were indeed due to the ten subcutaneously inoculated W256 tumor cells, we randomly allocated the data of these 27 samples (Number 1 to Number 27) into three groups. We tried three random allocations, and the numbers in these three groups are shown in [Table 2](#table-2){ref-type="table"}. In each iteration, we used the data of group 1 as the control group. When we used the previous criteria to screen differential urinary proteins, it was found that the adjusted *P*-values value on days 13 and 21 were all \>0.05. No differential proteins were selected in these three randomly allocated trials. Details are shown in [Tables S2](#supp-4){ref-type="supplementary-material"}, [S3](#supp-5){ref-type="supplementary-material"} and [S4](#supp-6){ref-type="supplementary-material"}.

10.7717/peerj.7717/table-2

###### Random allocation of the twenty-seven urine samples.

![](peerj-07-7717-g006)

  **Randomly allocated**   **Group 1**                       **Group 2**                       **Group 3**                       Adjusted *P*-value
  ------------------------ --------------------------------- --------------------------------- --------------------------------- --------------------
  1                        1, 4, 5, 12, 13, 14, 19, 20, 21   2, 3, 7, 11, 15, 17, 18, 22, 23   6, 8, 9, 10, 16, 24, 25, 26, 27   NO
  2                        1, 2, 3, 12, 13, 15, 25, 26, 27   4, 5, 6, 10, 11, 14, 19, 20, 21   7, 8, 9, 16, 17, 18, 22, 23, 24   NO
  3                        1, 7, 9, 11, 13, 16, 19, 21, 22   3, 4, 5, 10, 17, 18, 20, 25, 26   2, 6, 8, 12, 14, 15, 23, 24, 27   NO

**Notes.**

Numbers 1--9 represent Rat 1-D0 to Rat 9-D0; Numbers 10--18 represent Rat 1-D13 to Rat 9-D13; Numbers 19--27 represent Rat 1-D21 to Rat 9-D21.

Discussion
==========

Urine is an early and sensitive biomarker source that has been used for the early detection of cancer either in both animal models or clinical patients ([@ref-3]; [@ref-27]). However, no tumor starts from thousands of tumor cells. In this study, we subcutaneously inoculated approximately ten tumor cells into each of nine rats. Unsupervised clustering analysis showed the good consistency after inoculation. A total of 34 and 59 differential proteins identified on days 13 and 21, respectively, and no urinary proteins changed after random allocation analysis.

After the functional enrichment analysis, we found that some enriched biological processes were reported to be associated with tumor progression. For example, (i) cell adhesion was usually reported to show a reduced number of tumor cells since 1962 ([@ref-12]); (ii) autophagic cell death occurs via the activation of autophagy, which has been reported to play roles in tumor suppression ([@ref-16]); (iii) the positive regulation of cell proliferation is a common characteristic of cancer, and the inhibition of cancer cell proliferation may serve as a potential target for cancer treatment ([@ref-11]); (iv) changes in extracellular matrix organization were reported with crucial roles in cancer metastasis ([@ref-9]; [@ref-22]); (v) positive regulation of blood coagulation was frequently reported in cancer progression ([@ref-24]); and (vi) angiogenesis is still considered a common characteristic of tumorigenesis in many studies ([@ref-1]; [@ref-20]; [@ref-36]).

In addition, we found that some pathways were reported to play important roles in cancer. For example, (i) autophagy was reported to inhibit tumor progression ([@ref-19]); (ii) the MSP-RON signaling pathway was reported to play important roles in epithelial tumorigenesis ([@ref-15]) and will facilitate metastasis in prostate cancer cells ([@ref-29]); (iii) tissue factor (TF) expressed by tumor cells was reported to facilitate lung tumor progression ([@ref-10]); (iv) upregulation of the pentose phosphate pathway (PPP) has been reported in several types of cancer ([@ref-21]); and (v) the enriched complement system pathway was reported to enhance the metastatic process of ovarian cancer cells ([@ref-5]). Our results indicated that even when limited tumor cells are present in the body, the urine proteome can reflect changes associated with cancer.

When comparing differential proteins identified in our research to W256 subcutaneously tumor-bearing model ([@ref-27]) and intracerebral W256 tumor model ([@ref-34]), we found that the proportion of overlapping proteins was small, and more than half of the differential proteins in each of the three tumor models were unique ([Fig. S2](#supp-2){ref-type="supplementary-material"}). Comparing the differential proteins of the model inoculated with ten W256 cells and the W256 subcutaneously tumor-bearing model showed 25 overlapping proteins. We hypothesized that these small overlapping proteins may be due to the very different numbers of W256 tumor cells in these two animal models. Upon comparing the differences in the urine proteome between the ten tumor cell inoculated model and the intracerebral W256 tumor model, only 16 differential proteins overlapped, indicating that differential proteins were very different when the same tumor cells existed in different body parts. We also suppose that these proteomic profiles were different because the changes observed in this study were related to the very early phase of the tumor. Despite the small proportion of overlapping proteins, we found that cell adhesion was enriched in GO biological process analysis using either the 25 or 16 common differential proteins. This reduction in cell adhesion is a common characteristic of tumor cells ([@ref-4]). These results suggest that although the tumor cell number and location differ, using limited tumor cells has the potential to simulate the early phase of tumor development.

Notably, it was difficult to ensure that exactly ten tumor cells were subcutaneously inoculated into each of nine rats. Given the limited number of animals in this preliminary study, a larger number of animals should be considered in future studies.

Conclusions
===========

In this study, we aimed to observe changes in the urine proteome when inoculating approximately ten tumor cells into nine rats. Our results indicated that (1) the urine proteome reflects changes associated with cancer, even with a limited number of tumor cells in the body, and (2) the urine proteome reflects pathophysiological changes in the body with extremely high sensitivity, providing the potential for a very early screening process in clinical patients.
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###### Functional analysis of differential proteins on day 13 and day 21

\(A\) Dynamic changes in cellular component on day 13. (B) Dynamic changes in cellular component on day 21. (C) Dynamic changes in molecular functions on day 13. (D) Dynamic changes in molecular functions on day 21.
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###### Venn diagram of differential urinary proteins in W256 subcutaneous tumor-bearing model, intracerebral W256 tumor model and model inoculated with ten W256 cells
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###### Identification and quantitation details of the urine proteome identified in rats subcutaneously inoculated with tumor cells
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###### Random allocation statistical analysis on the first trial
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###### Random allocation statistical analysis on the second trial
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###### Random allocation statistical analysis on the third trial
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